These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 17956194)

  • 41. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.
    Heinemann V; Quietzsch D; Gieseler F; Gonnermann M; Schönekäs H; Rost A; Neuhaus H; Haag C; Clemens M; Heinrich B; Vehling-Kaiser U; Fuchs M; Fleckenstein D; Gesierich W; Uthgenannt D; Einsele H; Holstege A; Hinke A; Schalhorn A; Wilkowski R
    J Clin Oncol; 2006 Aug; 24(24):3946-52. PubMed ID: 16921047
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gemcitabine doublets in advanced pancreatic cancer: should we move on?
    Rocha Lima CM; Flores AM
    J Clin Oncol; 2006 Jan; 24(3):327-9. PubMed ID: 16344312
    [No Abstract]   [Full Text] [Related]  

  • 43. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
    Ellenrieder V; König A; Seufferlein T
    Digestion; 2016; 94(1):44-9. PubMed ID: 27438590
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cytotoxic chemotherapy for pancreatic cancer: Advances to date and future directions.
    Xiong HQ; Carr K; Abbruzzese JL
    Drugs; 2006; 66(8):1059-72. PubMed ID: 16789792
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Emerging drugs in pancreatic cancer.
    Ducreux M; Boige V; Malka D
    Expert Opin Emerg Drugs; 2004 May; 9(1):73-89. PubMed ID: 15155137
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison.
    Sultana A; Ghaneh P; Cunningham D; Starling N; Neoptolemos JP; Smith CT
    BMC Cancer; 2008 Jul; 8():192. PubMed ID: 18611273
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chemotherapy for advanced pancreatic cancer.
    Chua YJ; Cunningham D
    Best Pract Res Clin Gastroenterol; 2006 Apr; 20(2):327-48. PubMed ID: 16549331
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gemcitabine maintenance therapy after gemcitabine and platinum drug chemotherapy for naive stage IIIB/IV squamous cell lung cancer: a phase II study.
    Hamai K; Fujitaka K; Kitaguchi S; Tamamoto S; Takao S; Nishida A; Furutama J; Horimasu Y; Masuda T; Miyamoto S; Awaya Y; Kondo T; Shoda H; Ishikawa N; Yamasaki M; Hattori N
    Anticancer Drugs; 2021 Aug; 32(7):767-772. PubMed ID: 33967202
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Gemcitabine-based combinations in inoperable pancreatic cancers].
    Louvet C; André T; Artru P
    Bull Cancer; 2002 Aug; 89 Spec No():S96-101. PubMed ID: 12449038
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer.
    Oettle H; Riess H
    Cancer; 2002 Aug; 95(4 Suppl):912-22. PubMed ID: 12209671
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma.
    Philip PA; Zalupski MM; Vaitkevicius VK; Arlauskas P; Chaplen R; Heilbrun LK; Adsay V; Weaver D; Shields AF
    Cancer; 2001 Aug; 92(3):569-77. PubMed ID: 11505401
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.
    Ko AH; Dito E; Schillinger B; Venook AP; Bergsland EK; Tempero MA
    J Clin Oncol; 2006 Jan; 24(3):379-85. PubMed ID: 16344320
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Current and future perspectives in advanced bladder cancer: is there a new standard?
    von der Maase H
    Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407).
    Mizusawa J; Fukutomi A; Katayama H; Ishii H; Ioka T; Okusaka T; Ueno H; Ueno M; Ikeda M; Mizuno N; Ozaka M; Fukuda H; Furuse J;
    Pancreatology; 2018 Oct; 18(7):841-845. PubMed ID: 30075908
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab.
    Van Loon K; Espinoza AM; Fogelman DR; Wolff RA; Javle MM; Iyer RV; Picozzi VJ; Martin LK; Bekaii-Saab T; Tempero MA; Foster NR; Kim GP; Ko AH
    Pancreas; 2014 Apr; 43(3):343-9. PubMed ID: 24622062
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
    Wagner AD; Buechner-Steudel P; Wein A; Schmalenberg H; Lindig U; Moehler M; Behrens R; Kleber G; Kuss O; Fleig WE
    Ann Oncol; 2007 Jan; 18(1):82-87. PubMed ID: 17030546
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials.
    Pujol JL; Barlesi F; Daurès JP
    Lung Cancer; 2006 Mar; 51(3):335-45. PubMed ID: 16478643
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.
    Scheithauer W; Schüll B; Ulrich-Pur H; Schmid K; Raderer M; Haider K; Kwasny W; Depisch D; Schneeweiss B; Lang F; Kornek GV
    Ann Oncol; 2003 Jan; 14(1):97-104. PubMed ID: 12488300
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.
    Yoo C; Hwang JY; Kim JE; Kim TW; Lee JS; Park DH; Lee SS; Seo DW; Lee SK; Kim MH; Han DJ; Kim SC; Lee JL
    Br J Cancer; 2009 Nov; 101(10):1658-63. PubMed ID: 19826418
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience.
    Li J; Merl M; Lee MX; Kaley K; Saif MW
    Expert Opin Drug Saf; 2010 Mar; 9(2):207-13. PubMed ID: 20095915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.